
## Michael S Conte

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1973533/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Society for Vascular Surgery Lower Extremity Threatened Limb Classification System: Risk stratification based on Wound, Ischemia, and foot Infection (WIfl). Journal of Vascular Surgery, 2014, 59, 220-234.e2.	1.1	1,106
2	Global vascular guidelines on the management of chronic limb-threatening ischemia. Journal of Vascular Surgery, 2019, 69, 3S-125S.e40.	1.1	841
3	Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. European Journal of Vascular and Endovascular Surgery, 2019, 58, S1-S109.e33.	1.5	741
4	Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: Management of asymptomatic disease and claudication. Journal of Vascular Surgery, 2015, 61, 2S-41S.e1.	1.1	624
5	Results of PREVENT III: A multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. Journal of Vascular Surgery, 2006, 43, 742-751.e1.	1.1	579
6	Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia. Journal of Vascular Surgery, 2009, 50, 1462-1473.e3.	1.1	383
7	Acute Limb Ischemia. New England Journal of Medicine, 2012, 366, 2198-2206.	27.0	273
8	The natural history of untreated severe or critical limb ischemia. Journal of Vascular Surgery, 2015, 62, 1642-1651.e3.	1.1	271
9	Evaluation and Treatment of Patients With Lower Extremity Peripheral ArteryÂDisease. Journal of the American College of Cardiology, 2015, 65, 931-941.	2.8	269
10	Risk stratification in critical limb ischemia: Derivation and validation of a model to predict amputation-free survival using multicenter surgical outcomes data. Journal of Vascular Surgery, 2008, 48, 1464-1471.	1.1	227
11	The ideal small arterial substitute: a search for the Holy Grail?. FASEB Journal, 1998, 12, 43-45.	0.5	218
12	Technical factors affecting autogenous vein graft failure: Observations from a large multicenter trial. Journal of Vascular Surgery, 2007, 46, 1180-1190.	1.1	211
13	Aspirin-Triggered Lipoxin and Resolvin E1 Modulate Vascular Smooth Muscle Phenotype and Correlate with Peripheral Atherosclerosis. American Journal of Pathology, 2010, 177, 2116-2123.	3.8	178
14	Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. Journal of Vascular Surgery, 2004, 39, 1178-1185.	1.1	168
15	Critical Limb Ischemia: Current Trends and Future Directions. Journal of the American Heart Association, 2016, 5, .	3.7	167
16	Disparity in Outcomes of Surgical Revascularization for Limb Salvage. Circulation, 2009, 119, 123-130.	1.6	165
17	Design and Rationale of the Best Endovascular Versus Best Surgical Therapy for Patients With Critical Limb Ischemia (BESTâ€CLI) Trial. Journal of the American Heart Association, 2016, 5, .	3.7	158
18	Effect of a Home-Based Exercise Intervention of Wearable Technology and Telephone Coaching on Walking Performance in Peripheral Artery Disease. JAMA - Journal of the American Medical Association, 2018, 319, 1665.	7.4	151

#	Article	IF	CITATIONS
19	Risk factors, medical therapies and perioperative events in limb salvage surgery: Observations from the PREVENT III multicenter trial. Journal of Vascular Surgery, 2005, 42, 456-464.	1.1	149
20	Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia. Journal of Vascular Surgery, 2008, 47, 774-781.e1.	1.1	142
21	Elevated C-reactive protein levels are associated with postoperative events in patients undergoing lower extremity vein bypass surgery. Journal of Vascular Surgery, 2007, 45, 2-9.	1.1	141
22	A systematic review and meta-analysis of revascularization outcomes of infrainguinal chronic limb-threatening ischemia. Journal of Vascular Surgery, 2018, 68, 624-633.	1.1	133
23	Refinement of survival prediction in patients undergoing lower extremity bypass surgery: Stratification by chronic kidney disease classification. Journal of Vascular Surgery, 2007, 45, 944-952.	1.1	125
24	Prospective multicenter study of quality of life before and after lower extremity vein bypass in 1404 patients with critical limb ischemia. Journal of Vascular Surgery, 2006, 44, 977-983.	1.1	116
25	Dâ€series resolvin attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury. FASEB Journal, 2013, 27, 2220-2232.	0.5	112
26	Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease. Circulation, 2017, 135, 241-250.	1.6	111
27	Vein graft failure. Journal of Vascular Surgery, 2015, 61, 203-216.	1.1	110
28	Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) and the (hoped for) dawn of evidence-based treatment for advanced limb ischemia. Journal of Vascular Surgery, 2010, 51, 69S-75S.	1.1	103
29	Infrainguinal vein bypass graft revision: Factors affecting long-term outcome. Journal of Vascular Surgery, 2004, 40, 916-923.	1.1	99
30	Surgical Intervention for Peripheral Arterial Disease. Circulation Research, 2015, 116, 1614-1628.	4.5	99
31	The impact of patient age and aortic size on the results of aortobifemoral bypass grafting1 1Competition of interest: none.Published online Mar 6, 2003. Journal of Vascular Surgery, 2003, 37, 1219-1225.	1.1	88
32	Systemic delivery of proresolving lipid mediators resolvin D <sub>2</sub> and maresin 1 attenuates intimal hyperplasia in mice. FASEB Journal, 2015, 29, 2504-2513.	0.5	88
33	Dâ€series resolvins inhibit murine abdominal aortic aneurysm formation and increase M2 macrophage polarization. FASEB Journal, 2016, 30, 4192-4201.	0.5	88
34	A systematic review for the screening for peripheral arterial disease in asymptomatic patients. Journal of Vascular Surgery, 2015, 61, 42S-53S.	1.1	87
35	A systematic review of treatment of intermittent claudication in the lower extremities. Journal of Vascular Surgery, 2015, 61, 54S-73S.	1.1	86
36	The Pro-Resolving Lipid Mediator Maresin 1 (MaR1) Attenuates Inflammatory Signaling Pathways in Vascular Smooth Muscle and Endothelial Cells. PLoS ONE, 2014, 9, e113480.	2.5	79

#	Article	IF	CITATIONS
37	Critical appraisal of surgical revascularization for critical limb ischemia. Journal of Vascular Surgery, 2013, 57, 8S-13S.	1.1	78
38	Society for Vascular Surgery limb stage and patient risk correlate with outcomes in an amputation prevention program. Journal of Vascular Surgery, 2016, 63, 1563-1573.e2.	1.1	77
39	Advances in Revascularization for Peripheral Artery Disease: Revascularization in PAD. Circulation Research, 2021, 128, 1885-1912.	4.5	77
40	Short-term physical inactivity impairs vascular function. Journal of Surgical Research, 2014, 190, 672-682.	1.6	76
41	Understanding Objective Performance Goals for Critical Limb Ischemia Trials. Seminars in Vascular Surgery, 2010, 23, 129-137.	2.8	75
42	Infrainguinal bypass grafting in patients with end-stage renal disease: Improving outcomes?. Journal of Vascular Surgery, 2001, 33, 1171-1178.	1.1	73
43	Multicenter phase I/II trial of the safety of allogeneic endothelial cell implants after the creation of arteriovenous access for hemodialysis use: The V-HEALTH study. Journal of Vascular Surgery, 2009, 50, 1359-1368.e1.	1.1	71
44	Introduction. Journal of Vascular Surgery, 2015, 61, 1S.	1.1	69
45	Interventions for lower extremity peripheral artery disease. Nature Reviews Cardiology, 2018, 15, 332-350.	13.7	69
46	A systematic review and meta-analysis of revascularization outcomes of infrainguinal chronic limb-threatening ischemia. Journal of Vascular Surgery, 2019, 69, 126S-136S.	1.1	69
47	Shortâ€Term, Highâ€Dose Fish Oil Supplementation Increases the Production of Omegaâ€3 Fatty Acid–Derived Mediators in Patients With Peripheral Artery Disease (the OMEGAâ€PAD I Trial). Journal of the American Heart Association, 2015, 4, e002034.	3.7	64
48	Bypass surgery versus endovascular interventions in severe or critical limb ischemia. Journal of Vascular Surgery, 2016, 63, 244-253.e11.	1.1	64
49	Survival prediction in patients with chronic limb-threatening ischemia who undergo infrainguinal revascularization. Journal of Vascular Surgery, 2019, 69, 137S-151S.e3.	1.1	60
50	The ideal small arterial substitute: a search for the Holy Grail?. FASEB Journal, 1998, 12, 43-45.	0.5	59
51	Pro-resolving lipid mediators in vascular disease. Journal of Clinical Investigation, 2018, 128, 3727-3735.	8.2	58
52	Outcomes of Neuroischemic Wounds Treated by a Multidisciplinary Amputation Prevention Service. Annals of Vascular Surgery, 2015, 29, 534-542.	0.9	56
53	Design and Rationale of the PREVENT III Clinical Trial: Edifoligide for the Prevention of Infrainguinal Vein Graft Failure. Vascular and Endovascular Surgery, 2005, 39, 15-23.	0.7	52
54	Growing Impact of Restenosis on the Surgical Treatment of Peripheral Arterial Disease. Journal of the American Heart Association, 2013, 2, e000345.	3.7	52

#	Article	IF	CITATIONS
55	Diabetic Revascularization: Endovascular Versus Open Bypass—Do We Have the Answer?. Seminars in Vascular Surgery, 2012, 25, 108-114.	2.8	51
56	Chemical Mediators of Inflammation and Resolution in Post-Operative Abdominal Aortic Aneurysm Patients. Inflammation, 2012, 35, 98-113.	3.8	49
57	Perivascular delivery of resolvin D1 inhibits neointimal hyperplasia in a rat model of arterialÂinjury. Journal of Vascular Surgery, 2017, 65, 207-217.e3.	1.1	49
58	Resolution of vascular injury: Specialized lipid mediators and their evolving therapeutic implications. Molecular Aspects of Medicine, 2017, 58, 72-82.	6.4	48
59	Resolvin D1 decreases abdominal aortic aneurysm formation by inhibiting NETosis in a mouse model. Journal of Vascular Surgery, 2018, 68, 93S-103S.	1.1	48
60	Regulation of Vein Graft Hyperplasia by Survivin, an Inhibitor of Apoptosis Protein. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 2081-2087.	2.4	46
61	Editor's Choice – Relationship Between Global Limb Anatomic Staging System (GLASS) and Clinical Outcomes Following Revascularisation for Chronic Limb Threatening Ischaemia in the Bypass Versus Angioplasty in Severe Ischaemia of the Leg (BASIL)-1 Trial. European Journal of Vascular and Endovascular Surgery, 2020, 60, 687-695.	1.5	43
62	Functional Outcomes After Lower Extremity Revascularization in Nursing Home Residents. JAMA Internal Medicine, 2015, 175, 951.	5.1	42
63	Genetic interventions for vein bypass graft disease: A review. Journal of Vascular Surgery, 2002, 36, 1040-1052.	1.1	41
64	Biosynthesis of proresolving lipid mediators by vascular cells and tissues. FASEB Journal, 2017, 31, 3393-3402.	0.5	41
65	Challenges of distal bypass surgery in patients with diabetes: Patient selection, techniques, and outcomes. Journal of Vascular Surgery, 2010, 52, 96S-103S.	1.1	40
66	Clinical Trials in Peripheral Vascular Disease. Circulation, 2014, 130, 1812-1819.	1.6	40
67	Resource utilization in the treatment of critical limb ischemia: the effect of tissue loss, comorbidities, and graft-related events. Journal of Vascular Surgery, 2006, 44, 971-975.	1.1	39
68	Influence of diabetes and perivascular allogeneic endothelial cell implants on arteriovenous fistula remodeling. Journal of Vascular Surgery, 2011, 54, 1383-1389.	1.1	39
69	Advancing beyond the "heart-healthy diet―for peripheral arterial disease. Journal of Vascular Surgery, 2015, 61, 265-274.	1.1	39
70	Fish Oil Increases Specialized Pro-resolving Lipid Mediators in PAD (The OMEGA-PAD II Trial). Journal of Surgical Research, 2019, 238, 164-174.	1.6	38
71	Society for Vascular Surgery appropriate use criteria for management of intermittent claudication. Journal of Vascular Surgery, 2022, 76, 3-22.e1.	1.1	37
72	Technical Factors in Lower-Extremity Vein Bypass Surgery: How Can We Improve Outcomes?. Seminars in Vascular Surgery, 2009, 22, 227-233.	2.8	36

#	Article	IF	CITATIONS
73	Meaningful change in 6-minute walk in people with peripheral artery disease. Journal of Vascular Surgery, 2021, 73, 267-276.e1.	1.1	36
74	Safety and feasibility of adjunctive dexamethasone infusion into the adventitia of the femoropopliteal artery following endovascular revascularization. Journal of Vascular Surgery, 2014, 59, 1016-1024.	1.1	35
75	Usefulness of autogenous bypass grafts originating distal to the groin. Journal of Vascular Surgery, 2002, 35, 48-55.	1.1	34
76	Molecular engineering of vein bypass grafts. Journal of Vascular Surgery, 2007, 45, A74-A81.	1.1	32
77	Risk factors for clinical failure after stent graft treatment for femoropopliteal occlusive disease. Journal of Vascular Surgery, 2012, 56, 998-1007.e1.	1.1	32
78	Thirty-day vein remodeling is predictive of midterm graft patency after lower extremity bypass. Journal of Vascular Surgery, 2013, 57, 9-18.	1.1	32
79	A systematic review and meta-analysis of revascularization outcomes of infrainguinal chronic limb-threatening ischemia. European Journal of Vascular and Endovascular Surgery, 2019, 58, S110-S119.	1.5	32
80	An integrated biochemical prediction model of all-cause mortality in patients undergoing lower extremity bypass surgery for advanced peripheral artery disease. Journal of Vascular Surgery, 2012, 56, 686-695.	1.1	31
81	Perivascular delivery of resolvin D1 inhibits neointimal hyperplasia in a rabbit vein graft model. Journal of Vascular Surgery, 2018, 68, 188S-200S.e4.	1.1	31
82	Survivin expression is up-regulated in vascular injury and identifies a distinct cellular phenotype. Journal of Vascular Surgery, 2005, 41, 682-690.	1.1	30
83	Determinants of midterm functional outcomes, wound healing, and resources used in a hospital-based limb preservation program. Journal of Vascular Surgery, 2017, 66, 1765-1774.	1.1	30
84	Impact of the coronavirus disease 2019 pandemic on an academic vascular practice and a multidisciplinary limb preservation program. Journal of Vascular Surgery, 2020, 72, 1850-1855.	1.1	30
85	Aspirin-triggered resolvin D1 attenuates PDGF-induced vascular smooth muscle cell migration via the cyclic adenosine monophosphate/protein kinase A (cAMP/PKA) pathway. PLoS ONE, 2017, 12, e0174936.	2.5	30
86	Factors associated with primary vein graft occlusion in a multicenter trial with mandated ultrasound surveillance. Journal of Vascular Surgery, 2014, 59, 996-1002.	1.1	29
87	Superficial femoral artery percutaneous intervention is an effective strategy to optimize inflow for distal origin bypass grafts. Journal of Vascular Surgery, 2007, 45, 740-743.	1.1	28
88	Nonrevascularization-based treatments in patients with severe or critical limb ischemia. Journal of Vascular Surgery, 2015, 62, 1330-1339.e13.	1.1	27
89	Predictors of major amputation despite patent bypass grafts. Journal of Vascular Surgery, 2016, 63, 1279-1288.	1.1	27
90	Cryopreserved saphenous vein as a last-ditch conduit for limb salvage. Journal of Vascular Surgery, 2017, 66, 844-849.	1.1	27

#	Article	IF	CITATIONS
91	Treatment With a Marine Oil Supplement Alters Lipid Mediators and Leukocyte Phenotype in Healthy Patients and Those With Peripheral Artery Disease. Journal of the American Heart Association, 2020, 9, e016113.	3.7	27
92	Critical review and evidence implications of paclitaxel drug-eluting balloons and stents in peripheral artery disease. Journal of Vascular Surgery, 2019, 70, 3-7.	1.1	26
93	Using the Society for Vascular Surgery Wound, Ischemia, and foot Infection classification to identify patients most likely to benefit from revascularization. Journal of Vascular Surgery, 2019, 70, 776-785.e1.	1.1	26
94	Comparing 6-minute walk versus treadmill walking distance as outcomes in randomized trials of peripheral artery disease. Journal of Vascular Surgery, 2020, 71, 988-1001.	1.1	25
95	Endovascular interventions for claudication do not meet minimum standards for the Society for Vascular Surgery efficacy guidelines. Journal of Vascular Surgery, 2021, 73, 1693-1700.e3.	1.1	25
96	Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial. Circulation, 2021, 144, 1104-1116.	1.6	25
97	Unidirectional and sustained delivery of the proresolving lipid mediator resolvin D1 from a biodegradable thin film device. Journal of Biomedical Materials Research - Part A, 2017, 105, 31-41.	4.0	23
98	Survival prediction in patients with chronic limb-threatening ischemia who undergo infrainguinal revascularization. European Journal of Vascular and Endovascular Surgery, 2019, 58, S120-S134.e3.	1.5	23
99	Circulating exosomes from patients with peripheral artery disease influence vascular cell migration and contain distinct microRNA cargo. JVS Vascular Science, 2020, 1, 28-41.	1.1	23
100	The Global Limb Anatomic Staging System is associated with outcomes of infrainguinal revascularization in chronic limb threatening ischemia. Journal of Vascular Surgery, 2021, 73, 2009-2020.e4.	1.1	23
101	Specialized pro-resolving lipid mediators in cardiovascular disease, diagnosis, and therapy. Advanced Drug Delivery Reviews, 2020, 159, 170-179.	13.7	22
102	The vascular surgeon-scientist: A 15-year report of the Society for Vascular Surgery Foundation/National Heart, Lung, and Blood Institute-mentored Career Development Award Program. Journal of Vascular Surgery, 2015, 61, 1050-1057.e3.	1.1	21
103	Prognostic value of the Society for Vascular Surgery Wound, Ischemia, and foot Infection (WIfI) classification in patients with no-option chronic limb-threatening ischemia. Journal of Vascular Surgery, 2018, 68, 1104-1113.e1.	1.1	21
104	Patient complexity by surgical specialty does not correlate with work relative value units. Surgery, 2020, 168, 371-378.	1.9	21
105	Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements. Journal of Clinical Lipidology, 2017, 11, 1289-1295.	1.5	19
106	A single nucleotide polymorphism in the p27Kip1 gene is associated with primary patency of lower extremity vein bypass grafts. Journal of Vascular Surgery, 2013, 57, 1179-1185.e2.	1.1	18
107	Vitamin D deficiency is associated with mortality and adverse vascular access outcomes in patients with end-stage renal disease. Journal of Vascular Surgery, 2014, 60, 176-183.	1.1	17
108	C-reactive protein and vein graft disease: evidence for a direct effect on smooth muscle cell phenotype via modulation of PDGF receptor-β. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 295, H1132-H1140.	3.2	16

#	Article	IF	CITATIONS
109	Pedal arterial calcification score is associated with the risk of major amputation in chronic limb-threatening ischemia. Journal of Vascular Surgery, 2022, 75, 270-278.e3.	1.1	16
110	Survivin Regulation of Vascular Injury. Trends in Cardiovascular Medicine, 2006, 16, 114-117.	4.9	15
111	Risk Factors for 30-Day Hospital Readmission in Patients Undergoing Treatment for Peripheral Artery Disease. Vascular and Endovascular Surgery, 2015, 49, 69-74.	0.7	15
112	The Global Limb Anatomic Staging System (GLASS) for CLTI: Improving Inter-Observer Agreement. Journal of Clinical Medicine, 2021, 10, 3454.	2.4	14
113	Reversible cerebral vasoconstriction syndrome is a rare cause of stroke after carotid endarterectomy. Journal of Vascular Surgery, 2016, 64, 1847-1850.	1.1	12
114	Novel association between bone mineral density scores and the prevalence of peripheral artery disease in both sexes. Vascular Medicine, 2017, 22, 13-20.	1.5	12
115	Relationship between kidney disease and endothelial function in peripheral artery disease. Journal of Vascular Surgery, 2014, 60, 1605-1611.	1.1	10
116	Primary Stenting in Femoropopliteal Occlusive Disease – What Is the Appropriate Role? –. Circulation Journal, 2015, 79, 704-711.	1.6	10
117	Analysis of nutritional habits and intake of polyunsaturated fatty acids in veterans with peripheral arterial disease. Vascular Medicine, 2015, 20, 432-438.	1.5	10
118	External validation of the Vascular Quality Initiative prediction model for survival in no-option chronic limb-threatening ischemia patients. Journal of Vascular Surgery, 2020, 72, 1659-1666.e1.	1.1	10
119	Implementing global chronic limb-threatening ischemia guidelines in clinical practice: Utility of the Society for Vascular Surgery Threatened Limb Classification System (WIfl). Journal of Vascular Surgery, 2020, 72, 1451-1452.	1.1	10
120	Living in a Food Desert is Associated with 30-day Readmission after Revascularization for Chronic Limb-Threatening Ischemia. Annals of Vascular Surgery, 2021, 70, 36-42.	0.9	10
121	Patients with depression are less likely to go home after critical limb revascularization. Journal of Vascular Surgery, 2021, 74, 178-186.e2.	1.1	10
122	Pedal arterial calcification score is associated with hemodynamic change and major amputation after infrainguinal revascularization for chronic limb-threatening ischemia. Journal of Vascular Surgery, 2022, 76, 1688-1697.e3.	1.1	10
123	Clinical correlates of red blood cell omega-3 fatty acid content in male veterans with peripheral arterial disease. Journal of Vascular Surgery, 2014, 60, 1325-1331.	1.1	9
124	Oral Resolvin D1 attenuates early inflammation but not intimal hyperplasia in a rat carotid angioplasty model. Prostaglandins and Other Lipid Mediators, 2020, 146, 106401.	1.9	9
125	Antegrade common femoral artery closure device use is associated with decreased complications. Journal of Vascular Surgery, 2020, 72, 1610-1617.e1.	1.1	9
126	Challenges of Distal Bypass Surgery in Patients with Diabetes. Journal of the American Podiatric Medical Association, 2010, 100, 429-438.	0.3	8

#	Article	IF	CITATIONS
127	Data, guidelines, and practice of revascularization for claudication. Journal of Vascular Surgery, 2017, 66, 911-915.	1.1	8
128	Depression Predicts Non-Home Discharge After Abdominal Aortic Aneurysm Repair. Annals of Vascular Surgery, 2021, 74, 131-140.	0.9	8
129	Validation of randomized controlled trial-derived models for the prediction of postintervention outcomes in chronic limb-threatening ischemia. Journal of Vascular Surgery, 2020, 71, 869-879.	1.1	7
130	Association of Health Status Scores With Cardiovascular and Limb Outcomes in Patients With Symptomatic Peripheral Artery Disease: Insights From the EUCLID (Examining Use of Ticagrelor in) Tj ETQq0 0 0 e016573.	rgBT_∕Ove 3.7	erloçk 10 Tf 50
131	Risk factors for venous thromboembolism after vascular surgery and implications for chemoprophylaxis strategies. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2022, 10, 585-593.e2.	1.6	7
132	A systematic review of patient-reported outcome measures patients with chronic limb-threatening ischemia. Journal of Vascular Surgery, 2022, 75, 1762-1775.	1.1	7
133	Increased Reintervention After Infrainguinal Revascularization for Chronic Limb-Threatening Ischemia in Women. Annals of Vascular Surgery, 2020, 69, 307-316.	0.9	6
134	Applicability of the Vascular Quality Initiative mortality prediction model for infrainguinal revascularization in a tertiary limb preservation center population. Journal of Vascular Surgery, 2022, 76, 505-512.e2.	1.1	6
135	Risk score for nonhome discharge after lower extremity bypass. Journal of Vascular Surgery, 2020, 71, 889-895.	1.1	5
136	Patient-Reported Outcome Measures in Symptomatic, Non–Limb-Threatening Peripheral Artery Disease: A State-of-the-Art Review. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS121011320.	3.9	5
137	Natural history of acute pediatric iliofemoral artery thrombosis treated with anticoagulation. Journal of Vascular Surgery, 2020, 72, 2027-2034.	1.1	4
138	Contemporary Experience with Paravisceral Aortic Aneurysm (PVAAA) Repair in a Tertiary Center. Annals of Vascular Surgery, 2021, 75, 368-379.	0.9	4
139	17R/S-Benzo-RvD1, a synthetic resolvin D1 analogue, attenuates neointimal hyperplasia in a rat model of acute vascular injury. PLoS ONE, 2022, 17, e0264217.	2.5	4
140	Pedal Arterial Calcification Score Correlates With Risk of Major Amputation in Chronic Limb-Threatening Ischemia. Journal of Vascular Surgery, 2020, 72, e337.	1.1	3
141	A novel preoperative risk score for nonhome discharge after elective thoracic endovascular aortic repair. Journal of Vascular Surgery, 2021, 73, 1549-1556.	1.1	3
142	Closure device use for common femoral artery antegrade access is higher risk than retrograde access. Annals of Vascular Surgery, 2021, 76, 49-58.	0.9	3
143	Precision Medicine Enables More TNM-Like Staging in Patients With Chronic Limb Threatening Ischemia. Frontiers in Cardiovascular Medicine, 2021, 8, 709904.	2.4	3
144	A critical appraisal of registry-based objective performance goals in peripheral arterial disease. Journal of Vascular Surgery, 2021, 74, 1008-1012.	1.1	3

#	Article	IF	CITATIONS
145	Analysis of a Machine Learning–Based Risk Stratification Scheme for Chronic Limb-Threatening Ischemia. JAMA Network Open, 2022, 5, e223424.	5.9	3
146	Building a Global Alliance in Vascular Surgery. European Journal of Vascular and Endovascular Surgery, 2019, 58, 318-319.	1.5	2
147	Building a global alliance in vascular surgery. Journal of Vascular Surgery, 2019, 70, 663-664.	1.1	2
148	Appropriate use of revascularization for claudication. Journal of Vascular Surgery, 2020, 71, 131.	1.1	2
149	A limb is a peninsula and no clinician is an island: Introducing the American Limb Preservation Society (ALPS). Foot & Ankle Surgery Techniques, Reports & Cases, 2021, 1, 100005.	0.1	2
150	Discussion: Open Surgical Revascularization for Wound Healing: Past Performance and Future Directions; and Discussion: Critical Evaluation of Endovascular Surgery for Limb Salvage. Plastic and Reconstructive Surgery, 2011, 127, 174S-176S.	1.4	1
151	Where do We Go to in the Treatment of Acute Limb Ischaemia?. European Journal of Vascular and Endovascular Surgery, 2020, 59, 171-172.	1.5	1
152	Invasive treatment of claudication: Time for better measures and better controls. Journal of Vascular Surgery, 2021, 74, 505.	1.1	1
153	Understanding value and patient complexity among common inpatient vascular surgery procedures. Journal of Vascular Surgery, 2021, 74, 1343-1353.e2.	1.1	1
154	Reply. Journal of Vascular Surgery, 2020, 71, 348-349.	1.1	0
155	Clinical Effectiveness and Resource Utilization of Surgery versus Endovascular Therapy for Chronic Limb–Threatening Ischemia. Annals of Vascular Surgery, 2020, 68, 510-521.	0.9	0
156	Reply. Journal of Vascular Surgery, 2020, 72, 1831-1832.	1.1	0
157	Abstract 17: The Association Between Erythrocyte n-3 Polyunsaturated Fatty Acids (n-3 PUFAs) Content and Inflammation in Male Patients With Peripheral Artery Disease (PAD). Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, .	2.4	Ο
158	Abstract 251: Effects of n-3 Fatty Acids Supplementation on Endothelial Function and Inflammation in Peripheral Artery Disease: The OMEGA-PAD Trial. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, .	2.4	0
159	Abstract 134: Short-Term, High-Dose Fish Oil Supplementation Increases the Production of Downstream n-3 Fatty Acid Metabolites in Patients With Peripheral Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, .	2.4	0
160	Abstract 318: Determinants of Red Blood Cell Omega-3-Fatty Acid Content in Patients With Peripheral Arterial Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, .	2.4	0
161	Abstract 314: Development of a Nanotube-coated Nitinol Stent for Delivery of Resolvin D1. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, .	2.4	0
162	Abstract 285: Rapid Change In Red Blood Cell PUFA Composition With High-dose Fish Oil Supplementation In Patients With Peripheral Artery Disease (PAD) Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, .	2.4	0

#	Article	IF	CITATIONS
163	Peripheral arterial disease (pathophysiology, presentation, prevention/management). , 2022, , 361-375.		0